Toxic and iatrogenic myopathies

Handbook of Clinical Neurology

Volumn 86, Issue , 2007, Pages 321-341

  Mastaglia, Frank L ^a   Argov, Zohar ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649308215     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)86016-7     Document Type: Review

References (252)

1. Adams E.M., Horowitz H.W., and Sundstrom W.R. Fibrous myopathy in association with pentazocine. Arch Intern Med 143 (1983) 2203-2204
2. Afifi A.K., Hajj G.A., Saad S., et al. Clofibrate-induced myotoxicity in rats. Temporal profile of myopathology. Eur Neurol 23 (1984) 182-197
3. Agostini B., and Noetzel H. Morphological study of muscle fibres and motor end-plates in tetanus. In: Walton J.N., Canal N., and Scarlato G. (Eds). Muscle Diseases (1970), Excerpta Medica, Amsterdam 123-127
4. Ahlgren J.D., Manz H.J., and Harvey J.C. Myopathy of chronic organophosphate poisoning: a clinical entity?. South Med J 72 (1979) 555-558 563
5. Alsheikh-Ali A.A., Ambrose M.S., Kuvin J.T., et al. The safety of rosuvastatin as used in common clinical practice. A postmarketing analysis. Circulation 111 (2005) 3051-3057
6. Anderson T.L., and Torrance C.A. Metabolic mechanisms of acute alcoholic myopathy. Neurology 34 (1984) 81
7. Anderson P.J., Song S.K., and Slotwiner P. The fine structure of spheromembranous degeneration of skeletal muscle induced by vincristine. J Neuropathol Exp Neurol 26 (1967) 15-24
8. Anderson N.E., Lynch N.M., and O'Brien K.P. Disabling neurological complications of amiodarone. Aust N Z J Med 15 (1985) 300-304
9. Argov Z. Drug-induced myopathies. Curr Opin Neurol 13 (2000) 541-545
10. Argov Z., and Mastaglia F.L. Drug therapy: disorders of neuromuscular transmission caused by drugs. N Engl J Med 301 (1979) 409-413
11. Argov Z., and Mastaglia F.L. Drug-induced peripheral neuropathies. Br Med J 1 (1979) 663-666
12. Arnaudo E., Dalakas M., Shanske S., et al. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 337 (1991) 508-510
13. Azevedo-Marques M.M., Cupo P., Coimbra T.M., et al. Myonecrosis, myoglobinuria and acute renal failure induced by South American rattlesnake (Crotalus durissus terrificus) envenomation in Brazil. Toxicon 23 (1985) 631-636
14. Baker S.K., Goodwin S., Sur M., et al. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve 30 (2004) 799-802
15. Bargossi A.M., Battino M., Gaddi A., et al. Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Int J Clin Lab Res 24 (1994) 171-176
16. Belongia E.A., Hedberg C.W., Gleich G.J., et al. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med 323 (1990) 357-365
17. Bennett H.S., Spiro A.J., Pollack M.A., et al. Ipecac-induced myopathy simulating dermatomyositis. Neurology 32 (1982) 91-94
18. Bennett R.H., and Forman H.R. Hypokalemic periodic paralysis in chronic toluene exposure. Arch Neurol 37 (1980) 673
19. Berlin R. Haff disease in Sweden. Acta Med Scand 129 (1948) 560-572
20. Billis A.G., Kastanakis S., Giamarellou H., et al. Acute renal failure after a meal of quail. Lancet 2 (1971) 702
21. Bleske B.E., Willis R.A., Anthony M., et al. The effect of pravastatin and atorvastatin on coenzyme Q10. Am Heart J 142 (2001) E2
22. Blessing W., and Walsh J.C. Myotonia precipitated by propranolol therapy. Lancet 1 (1977) 73-74
23. Blumberg A., and Marti H.R. Acute rhabdomyolysis following administration of succinylcholine. Schweiz Med Wochenschr 114 (1984) 1068-1071
24. Bowyer S.L., LaMothe M.P., and Hollister J.R. Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol 76 (1985) 234-242
25. Bradley W.G., Lassman L.P., Pearce G.W., et al. The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies. J Neurol Sci 10 (1970) 107-131
26. Bradley W.G., Fewings J.D., Harris J.B., et al. Emetine myopathy in the rat. Br J Pharmacol 57 (1976) 29-31
27. Braunstein Jr. P.W., and DeGirolami U. Experimental corticosteroid myopathy. Acta Neuropathol (Berl) 55 (1981) 167-172
28. Bretag A.H., Dawe S.R., and Moskwa A.G. Chemically induced myotonia in amphibia. Nature 286 (1980) 625-626
29. Briner V., Colombi A., Brunner W., et al. Acute rhabdomyolysis. Schweiz Med Wochenschr 116 (1986) 198-208
30. Britt Jr. C.W., Light R.R., Peters B.H., et al. Rhabdomyolysis during treatment with epsilon-aminocaproic acid. Arch Neurol 37 (1980) 187-188
31. Brown J.A., Wollmann R.L., and Mullan S. Myopathy induced by epsilon-aminocaproic acid. Case report. J Neurosurg 57 (1982) 130-134
32. Brumback R.A., Gerst J.W., and Knull H.R. High energy phosphate depletion in a model of defective muscle glycolysis. Muscle Nerve 6 (1983) 52-55
33. Buchholz U., Mouzin E., Dickey R., et al. Haff disease: from the Baltic Sea to the U.S. shore. Emerg Infect Dis 6 (2000) 192-195
34. Campellone J.V., Lacomis D., Kramer D.J., et al. Acute myopathy after liver transplantation. Neurology 50 (1998) 46-53
35. Carroll G.J., Will R.K., Peter J.B., et al. Penicillamine induced polymyositis and dermatomyositis. J Rheumatol 14 (1987) 995-1001
36. Chaboche C., Nordmann Y., Fontaine J.L., et al. Myoglobinuria following anesthesia [author's translation]. Arch Fr Pediatr 39 (1982) 169-171
37. Chalmers A.C., Greco C.M., and Miller R.G. Prognosis in AZT myopathy. Neurology 41 (1991) 1181-1184
38. Chappel R., and Willems J. D-penicillamine-induced myositis in rheumatoid arthritis. Clin Rheumatol 15 (1996) 86-87
39. Chariot P., Monnet I., and Gherardi R. Cytochrome c oxidase reaction improves histopathological assessment of zidovudine myopathy. Ann Neurol 34 (1993) 561-565
40. Chemali K.R., Suarez J.I., and Katirji B. Acute hypokalemic paralysis associated with long-term lithium therapy. Muscle Nerve 24 (2001) 297-298
41. Choucair A.K., and Ziter F.A. Pentazocine abuse masquerading as familial myopathy. Neurology 34 (1984) 524-527
42. Chui L.A., Neustein H., and Munsat T.L. Tubular aggregates in subclinical alcoholic myopathy. Neurology 25 (1975) 405-412
43. Cirigliano G., Della Rossa A., Tavoni A., et al. Polymyositis occurring during alpha-interferon treatment for malignant melanoma: a case report and review of the literature. Rheumatol Int 19 (1999) 65-67
44. Clark A.F., DeMartino G.N., and Wildenthal K. Effects of glucocorticoid treatment on cardiac protein synthesis and degradation. Am J Physiol 250 (1986) C821-C827
45. Clark A.F., and Vignos Jr. P.J. Experimental corticosteroid myopathy: effect on myofibrillar ATPase activity and protein degradation. Muscle Nerve 2 (1979) 265-273
46. Clouston P.D., and Donnelly P.E. Acute necrotising myopathy associated with amiodarone therapy. Aust N Z J Med 19 (1989) 483-485
47. Cogen F.C., Rigg G., Simmons J.L., et al. Phencyclidine-associated acute rhabdomyolysis. Ann Intern Med 88 (1978) 210-212
48. Comi G., Testa D., Cornelio F., et al. Potassium depletion myopathy: a clinical and morphological study of six cases. Muscle Nerve 8 (1985) 17-21
49. Coomes E.N. The rate of recovery of reversible myopathies and the effects of anabolic agents in steroid myopathy. Neurology 15 (1965) 523-530
50. Dalakas M.C., Illa I., Pezeshkpour G.H., et al. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 322 (1990) 1098-1105
51. Dietrich L.L., Bridges A.J., and Albertini M.R. Dermatomyositis after interferon alpha treatment. Med Oncol 17 (2000) 64-69
52. Douglass J.A., Tuxen D.V., Horne M., et al. Myopathy in severe asthma. Am Rev Respir Dis 146 (1992) 517-519
53. Dreier J.P., and Endres M. Statin-associated rhabdomyolysis triggered by grapefruit consumption. Neurology 62 (2004) 670
54. Drenckhahn D., and Lullmann-Rauch R. Experimental myopathy induced by amphiphilic cationic compounds including several psychotropic drugs. Neuroscience 4 (1979) 549-562
55. Dropcho E.J., and Soong S.J. Steroid-induced weakness in patients with primary brain tumors. Neurology 41 (1991) 1235-1239
56. Duane D.D., and Engel A.G. Emetine myopathy. Neurology 20 (1970) 733-739
57. DuBois D.C., and Almon R.R. Disuse atrophy of skeletal muscle is associated with an increase in number of glucocorticoid receptors. Endocrinology 107 (1980) 1649-1651
58. DuBois D.C., and Almon R.R. A possible role for glucocorticoids in denervation atrophy. Muscle Nerve 4 (1981) 370-373
59. DuBois D.C., and Almon R.R. Glucocorticoid sites in skeletal muscle: adrenalectomy, maturation, fiber type, and sex. Am J Physiol 247 (1984) E118-E125
60. Duchen L.W. Changes in the electron microscopic structure of slow and fast skeletal muscle fibres of the mouse after the local injection of botulinum toxin. J Neurol Sci 14 (1971) 61-74
61. Duchen L.W. An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse. J Neurol Sci 14 (1971) 47-60
62. Duchen L.W. The effects of tetanus toxin on the motor end-plates of the mouse. An electron microscopic study. J Neurol Sci 19 (1973) 153-167
63. Eadie M.J., and Ferrier T.M. Chloroquine myopathy. J Neurol Neurosurg Psychiatry 29 (1966) 331-337
64. Eidson M., Philen R.M., Sewell C.M., et al. L-tryptophan and eosinophilia-myalgia syndrome in New Mexico. Lancet 335 (1990) 645-648
65. Ekbom K., Hed R., Kirstein L., et al. Muscular affections in chronic alcoholism. Arch Neurol 10 (1964) 449-458
66. England J.D., Walsh J.C., Stewart P., et al. Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors - simvastatin and pravastatin. Aust N Z J Med 25 (1995) 374-375
67. Estes M.L., Ewing-Wilson D., Chou S.M., et al. Chloroquine neuromyotoxicity. Clinical and pathologic perspective. Am J Med 82 (1987) 447-455
68. Fardeau M., Tome F.M., and Simon P. Muscle and nerve changes induced by perhexiline maleate in man and mice. Muscle Nerve 2 (1979) 24-36
69. Farmer J.A. Learning from the cerivastatin experience. Lancet 358 (2001) 1383-1385
70. Fernando Roth R., Itabashi H., Louie J., et al. Amiodarone toxicity: myopathy and neuropathy. Am Heart J 119 (1990) 1223-1225
71. Fohlman J., and Eaker D. Isolation and characterization of a lethal myotoxic phospholipase A from the venom of the common sea snake Enhydrina schistosa causing myoglobinuria in mice. Toxicon 15 (1977) 385-393
72. Forfar J.C., Brown G.J., and Cull R.E. Proximal myopathy during beta-blockade. Br Med J 2 (1979) 1331-1332
73. Fortenberry J.D. Gasoline sniffing. Am J Med 79 (1985) 740-744
74. Franc S., Dejager S., Bruckert E., et al. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther 17 (2003) 459-465
75. Franca F.O., Benvenuti L.A., Fan H.W., et al. Severe and fatal mass attacks by 'killer' bees (Africanized honey bees - Apis mellifera scutellata) in Brazil: clinicopathological studies with measurement of serum venom concentrations. Q J Med 87 (1994) 269-282
76. Friedman E.J. Death from ipecac intoxication in a patient with anorexia nervosa. Am J Psychiatry 141 (1984) 702-703
77. Frisk-Holmberg M., Jorfeldt L., Juhlin-Dannfelt A., et al. Metabolic changes in muscle on long-term alprenolol therapy. Clin Pharmacol Ther 26 (1979) 566-571
78. Fux R., Morike K., Gundel U.F., et al. Ezetimibe and statin-associated myopathy. Ann Intern Med 140 (2004) 671-672
79. Gabow P.A., Kaehny W.D., and Kelleher S.P. The spectrum of rhabdomyolysis. Medicine (Baltimore) 61 (1982) 141-152
80. Gadbut A.P., Caruso A.P., and Galper J.B. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. J Mol Cell Cardiol 27 (1995) 2397-2402
81. Gaist D., Rodriguez L.A., Huerta C., et al. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 12 (2001) 565-569
82. Gala S., and Katelaris C.H. Rhabdomyolysis due to redback spider envenomation. Med J Aust 157 (1992) 66
83. Gardiner P.F., and Edgerton V.R. Contractile responses of rat fast-twitch and slow-twitch muscles to glucocorticoid treatment. Muscle Nerve 2 (1979) 274-281
84. Gherardi R.K., and Authier F.J. Aluminum inclusion macrophagic myofasciitis: a recently identified condition. Immunol Allergy Clin North Am 23 (2003) 699-712
85. Gherardi R.K., Coquet M., Cherin P., et al. Macrophagic myofasciitis: an emerging entity. Groupe d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l'Association Francaise contre les Myopathies (AFM). Lancet 352 (1998) 347-352
86. Gherardi R.K., Coquet M., Cherin P., et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 124 (2001) 1821-1831
87. Gibbs J.M. A case of rhabdomyolysis associated with suxamethonium. Anaesth Intensive Care 6 (1978) 141-145
88. Goldman J.A., Fishman A.B., Lee J.E., et al. The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis. Arthritis Rheum 32 (1989) 358-359
89. Grob D. Rhabdomyolysis and drug-related myopathies. Curr Opin Rheumatol 2 (1990) 908-915
90. Gruener R., and Stern L.Z. Corticosteroids. Effects on muscle membrane excitability. Arch Neurol 26 (1972) 181-185
91. Grundy S.M. The issue of statin safety. Where do we stand?. Circulation 111 (2005) 3016-3019
92. Gutierrez J.M., Arroyo O., Chaves F., et al. Pathogenesis of myonecrosis induced by coral snake (Micrurus nigrocinctus) venom in mice. Br J Exp Pathol 67 (1986) 1-12
93. Gutierrez J.M., Chaves F., Gene J.A., et al. Myonecrosis induced in mice by a basic myotoxin isolated from the venom of the snake Bothrops nummifer (jumping viper) from Costa Rica. Toxicon 27 (1989) 735-745
94. Gutierrez J.M., Ownby C.L., and Odell G.V. Isolation of a myotoxin from Bothrops asper venom: partial characterization and action on skeletal muscle. Toxicon 22 (1984) 115-128
95. Gutmann L. Critical illness neuropathy and myopathy. Arch Neurol 56 (1999) 527-528
96. Hales D.S., Scott R., and Lewi H.J. Myopathy due to mercaptopropionyl glycine. Br Med J (Clin Res Ed) 285 (1982) 939
97. Haller R.G. Experimental acute alcoholic myopathy - a histochemical study. Muscle Nerve 8 (1985) 195-203
98. Haller R.G., and Drachman D.B. Alcoholic rhabdomyolysis: an experimental model in the rat. Science 208 (1980) 412-415
99. Haller R.G., and Knochel J.P. Skeletal muscle disease in alcoholism. Med Clin North Am 68 (1984) 91-103
100. Harris J.B., and Maltin C.A. Myotoxic activity of the crude venom and the principal neurotoxin, taipoxin, of the Australian taipan, Oxyuranus scutellatus. Br J Pharmacol 76 (1982) 61-75
101. Hayes D.J., Byrne E., Shoubridge E.A., et al. Experimentally induced defects of mitochondrial metabolism in rat skeletal muscle. Biological effects of the NADH: coenzyme Q reductase inhibitor diphenyleneiodonium. Biochem J 229 (1985) 109-117
102. Hengstman G.J., Vogels O.J., ter Laak H.J., et al. Myositis during long-term interferon-alpha treatment. Neurology 54 (2000) 2186
103. Hertzman P.A., Blevins W.L., Mayer J., et al. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N Engl J Med 322 (1990) 869-873
104. Hickson R.C., and Davis J.R. Partial prevention of glucocorticoid-induced muscle atrophy by endurance training. Am J Physiol 241 (1981) E226-E232
105. Higuchi I., Takahashi K., Nakahara K., et al. Experimental germanium myopathy. Acta Neuropathol (Berl) 82 (1991) 55-59
106. Hoefnagel D., Jalbert E.O., Publow D.G., et al. Progressive fibrosis of the deltoid muscles. J Pediatr 92 (1978) 79-81
107. Hoke A., Rewcastle N.B., and Zochodne D.W. Acute quadriplegic myopathy unrelated to steroids or paralyzing agents: quantitative EMG studies. Can J Neurol Sci 26 (1999) 325-329
108. Horber F.F., Scheidegger J.R., Grunig B.E., et al. Thigh muscle mass and function in patients treated with glucocorticoids. Eur J Clin Invest 15 (1985) 302-307
109. Huang S.Y., and Perez J.C. A comparative electron microscopic study of myonecrosis induced by Crotalus atrox (Western diamondback rattlesnake) in gray woodrats and mice. Toxicon 20 (1982) 443-449
110. Hughes J.T., Esiri M., Oxbury J.M., et al. Chloroquine myopathy. Q J Med 40 (1971) 85-93
111. Jagose J.T., and Bailey R.R. Muscle weakness due to colchicine in a renal transplant recipient. N Z Med J 110 (1997) 343
112. Jamal S.M., Eisenberg M.J., and Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J 147 (2004) 956-965
113. Jenkins P., and Emerson P.A. Myopathy induced by rifampicin. Br Med J (Clin Res Ed) 283 (1981) 105-106
114. Jennings A.E., Levey A.S., and Harrington J.T. Amoxapine-associated acute renal failure. Arch Intern Med 143 (1983) 1525-1527
115. Johnson T.E., Zhang X., Bleicher K.B., et al. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol Appl Pharmacol 200 (2004) 237-250
116. Kahn L.B., and Meyer J.S. Acute myopathy in chronic alcoholism: a study of 22 autopsy cases, with ultrastructural observations. Am J Clin Pathol 53 (1970) 516-530
117. Kaiser P., Tesch P.A., Thorsson A., et al. Skeletal muscle glycolysis during submaximal exercise following acute beta-adrenergic blockade in man. Acta Physiol Scand 123 (1985) 285-291
118. Kalkner K.M., Ronnblom L., Karlsson Parra A.K., et al. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. Q J Med 91 (1998) 393-399
119. Kanda F., Takatani K., Okuda S., et al. Preventive effects of insulin-like growth factor-I on steroid-induced muscle atrophy. Muscle Nerve 22 (1999) 213-217
120. Kane M.J., Silverman L.R., Rand J.H., et al. Myonecrosis as a complication of the use of epsilon amino-caproic acid: a case report and review of the literature. Am J Med 85 (1988) 861-863
121. Karalliedde L., and Henry J.A. Effects of organophosphates on skeletal muscle. Hum Exp Toxicol 12 (1993) 289-296
122. Karlsson J. Muscle fibre composition, short term 1- + 2- and 1-blockade and endurance exercise performance in healthy young men. Drugs 25 (1983) 241-246
123. Karpati G. Denervation and disuse atrophy of skeletal muscles: involvement of endogenous glucocorticoid hormones?. Trends Neurosci 7 (1984) 61-62
124. Kaufman L.D. Neuromuscular manifestations of the L-tryptophan-associated eosinophilia-myalgia syndrome. Curr Opin Rheumatol 2 (1990) 896-900
125. Kennedy M. Cardiac glycoside toxicity. An unusual manifestation of drug addiction. Med J Aust 2 (1981) 686 688-689
126. Khaleeli A.A., Edwards R.H., Gohil K., et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf) 18 (1983) 155-166
127. Kilpatrick C., Braund W., and Burns R. Myopathy with myasthenia features possibly induced by codeine linctus. Med J Aust 2 (1982) 410
128. Knochel J.P. Rhabdomyolysis and myoglobinuria. Ann Rev Med 33 (1982) 435-443
129. Kovanen J., Somer H., and Schroeder P. Acute myopathy associated with gasoline sniffing. Neurology 33 (1983) 629-631
130. Kuncl R.W., Duncan G., Watson D., et al. Colchicine myopathy and neuropathy. N Engl J Med 316 (1987) 1562-1568
131. Kwiecinski H. Myotonia induced by chemical agents. Crit Rev Toxicol 8 (1981) 279-310
132. Laaksonen R., Jokelainen K., Laakso J., et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 77 (1996) 851-854
133. Lacomis D., Giuliani M.J., Van Cott A., et al. Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects. Ann Neurol 40 (1996) 645-654
134. Lacomis D., Zochodne D.W., and Bird S.J. Critical illness myopathy. Muscle Nerve 23 (2000) 1785-1788
135. Lamperti C., Naini A.B., Lucchini V., et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 62 (2005) 1709-1712
136. Lane R.J., McLelland N.J., Martin A.M., et al. Epsilon aminocaproic acid (EACA) myopathy. Postgrad Med J 55 (1979) 282-285
137. Lane R.J., and Radoff F.M. Alcohol and serum creatinine kinase levels. Ann Neurol 10 (1981) 581-583
138. Langer T., and Levy R.I. Acute muscular syndrome associated with administration of clofibrate. N Engl J Med 279 (1968) 856-858
139. Lazarus A.L., and Toglia J.U. Fatal myoglobinuric renal failure in a patient with tardive dyskinesia. Neurology 35 (1985) 1055-1057
140. Leonard J.P., and Salpeter M.M. Agonist-induced myopathy at the neuromuscular junction is mediated by calcium. J Cell Biol 82 (1979) 811-819
141. Lilja J.J., Neuvonen M., and Neuvonen P.J. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 58 (2004) 56-60
142. Litin S.C., and Anderson C.F. Nicotinic acid-associated myopathy: a report of three cases. Am J Med 86 (1989) 481-483
143. Livingstone I., Johnson M.A., and Mastaglia F.L. Effects of dexamethasone on fibre subtypes in rat muscle. Neuropathol Appl Neurobiol 7 (1981) 381-398
144. Lullmann H., Lullmann-Rauch R., and Wassermann O. Lipidosis induced by amphiphilic cationic drugs. Biochem Pharmacol 27 (1978) 1103-1108
145. Magarian G.J., Lucas L.M., and Colley C. Gemfibrozil-induced myopathy. Arch Intern Med 151 (1991) 1873-1874
146. Mak K.H., Boey M.L., Wan S.H., et al. Myocardial and skeletal muscle injuries following adenine arabinoside therapy. Aust N Z J Med 20 (1990) 811-813
147. Mariani C., Meola G., Meroni P.L., et al. Pentazocine-induced neuromuscular syndromes: clinical, immunological and histopathological studies in two cases. Acta Neuropathol Suppl (Berl) 7 (1981) 246-248
148. Martin F.C., Slavin G., and Levi A.J. Alcoholic muscle disease. Br Med Bull 38 (1982) 53-56
149. Martin F.C., Levi A.J., Slavin G., et al. Glycogen content and activities of key glycolytic enzymes in muscle biopsies from control subjects and patients with chronic alcoholic skeletal myopathy. Clin Sci (Lond) 66 (1984) 69-78
150. Martin F., Ward K., Slavin G., et al. Alcoholic skeletal myopathy, a clinical and pathological study. Q J Med 55 (1985) 233-251
151. Martinez A.J., Hooshmand H., and Faris A.A. Acute alcoholic myopathy. Enzyme histochemistry and electron microscopic findings. J Neurol Sci 20 (1973) 245-252
152. Massa R., Carpenter S., Holland P., et al. Loss and renewal of thick myofilaments in glucocorticoid-treated rat soleus after denervation and reinnervation. Muscle Nerve 15 (1992) 1290-1298
153. Mastaglia F.L. Adverse effects of drugs on muscle. Drugs 24 (1982) 304-321
154. Mastaglia F.L. Drug-induced myopathies. Practical Neurology 6 (2006) 4-13
155. Mastaglia F.L., and Argov Z. Drug-induced neuromuscular disorders in man. In: Walton J.N. (Ed). Disorders of Voluntary Muscle (1988), Churchill Livingstone, Edinburgh 873-906
156. Mastaglia F.L., Gardner-Medwin D., and Hudgson P. Muscle fibrosis and contractures in a pethidine addict. Br Med J 4 (1971) 532-533
157. Mastaglia F.L., Papadimitriou J.M., Dawkins R.L., et al. Vacuolar myopathy associated with chloroquine, lupus erythematosus and thymoma. Report of a case with unusual mitochondrial changes and lipid accumulation in muscle. J Neurol Sci 34 (1977) 315-328
158. Mateer J.E., Farrell B.J., Chou S.S., et al. Reversible ipecac myopathy. Arch Neurol 42 (1985) 188-190
159. Max S.R., Konagaya M., and Konagaya Y. Drug-induced myopathies: examples of cellular mechanisms. Muscle Nerve 9 (1986) 33
160. Mebs D., and Ownby C.L. Myotoxic components of snake venoms: their biochemical and biological activities. Pharmacol Ther 48 (1990) 223-236
161. Medsger Jr. T.A. Tryptophan-induced eosinophilia-myalgia syndrome. N Engl J Med 322 (1990) 926-928
162. Meier C., Kauer B., Muller U., et al. Neuromyopathy during chronic amiodarone treatment. A case report. J Neurol 220 (1979) 231-239
163. Mhiri C., Baudrimont M., Bonne G., et al. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann Neurol 29 (1991) 606-614
164. Miranda N., Oliveira P., Frade M.J., et al. Myositis with tretinoin. Lancet 344 (1994) 1096
165. Miro O., Salmeron J.M., Masanes F., et al. Acute quadriplegic myopathy with myosin-deficient muscle fibres after liver transplantation: defining the clinical picture and delimiting the risk factors. Transplantation 67 (1999) 1144-1151
166. Mitsumoto H., Wilbourn A.J., and Subramony S.H. Generalized myokymia and gold therapy. Arch Neurol 39 (1982) 449-450
167. Modi K.B., Horn E.H., and Bryson S.M. Theophylline poisoning and rhabdomyolysis. Lancet 2 (1985) 160-161
168. Mori M., Satoh A., Tsujihata M., et al. Myotonic discharges in a case of licorice-induced hypokalemic myopathy. Rinsho Shinkeigaku 25 (1985) 560-564
169. Nakahara K., Kuriyama M., Sonoda Y., et al. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicol Appl Pharmacol 152 (1998) 99-106
170. Neville H.E., Maunder-Sewry C.A., McDougall J., et al. Chloroquine-induced cytosomes with curvilinear profiles in muscle. Muscle Nerve 2 (1979) 376-381
171. Ng R.H., and Howard B.D. Mitochondria and sarcoplasmic reticulum as model targets for neurotoxic and myotoxic phospholipases A2. Proc Natl Acad Sci U S A 77 (1980) 1346-1350
172. Omar M.A., and Wilson J.P. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 36 (2002) 288-295
173. Ori M., and Ikeda H. Spider venoms and spider toxins. J Toxicol Toxin Rev 17 (1998) 405-426
174. Ownby C.L., and Odell G.V. Pathogenesis of skeletal muscle necrosis induced by tarantula venom. Exp Mol Pathol 38 (1983) 283-296
175. Palmer E.P., and Guay A.T. Reversible myopathy secondary to abuse of ipecac in patients with major eating disorders. N Engl J Med 313 (1985) 1457-1459
176. Panegyres P.K., Papadimitriou J.M., Hollingsworth P.N., et al. Vesicular changes in the myopathies of AIDS. Ultrastructural observations and their relationship to zidovudine treatment. J Neurol Neurosurg Psychiatry 53 (1990) 649-655
177. Papadimitriou A., Hadjigeorgiou G.M., Tsairis P., et al. Myoglobinuria due to quail poisoning. Eur Neurol 36 (1996) 142-145
178. Papadimitriou J.M., and Mastaglia F.L. Myopathy induced by mulga snake venom: a model for the study of muscle degeneration and regeneration. ICSN 294, Basic Research in Myology, Proceedings of the Second International Congress on Muscle Disease (1973), Excerpta Medica, Amsterdam 426-437
179. Pasternak R.C., Smith Jr. S.C., Bairey-Merz C.N., et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 40 (2002) 567-572
180. Perea M., Picon M., Miro O., et al. Acute quadriplegic myopathy with loss of thick (myosin) filaments following heart transplantation. J Heart Lung Transplant 20 (2001) 1136-1141
181. Perkoff G.T., Hardy P., and Velez-Garcia E. Reversible acute muscular syndrome in chronic alcoholism. N Engl J Med 274 (1966) 1277-1285
182. Petajan J.H., Townsend J., and Currey K.M. Ethchlorvynol (Placidyl) may produce tubular aggregates in skeletal muscle. Electroencephalogr Clin Neurophysiol 64 (1986) 54
183. Phillips P.S., Haas R.H., Bannykh S., et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137 (2002) 581-585
184. Pinals R.S. Diffuse fasciculations induced by D-penicillamine. J Rheumatol 10 (1983) 809-810
185. Rannels S.R., Rannels D.E., Pegg A.E., et al. Glucocorticoid effects on peptide-chain initiation in skeletal muscle and heart. Am J Physiol 235 (1978) E134-E139
186. Reaven P., and Witztum J.L. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 109 (1988) 597-598
187. Reeback J., Benton S., Swash M., et al. Penicillamine-induced neuromyotonia. Br Med J 1 (1979) 1464-1465
188. Rich M.M., and Pinter M.J. Sodium channel inactivation in an animal model of acute quadriplegic myopathy. Ann Neurol 50 (2001) 26-33
189. Rich M.M., Teener J.W., Raps E.C., et al. Muscle is electrically inexcitable in acute quadriplegic myopathy. Neurology 46 (1996) 731-736
190. Rich M.M., Bird S.J., Raps E.C., et al. Direct muscle stimulation in acute quadriplegic myopathy. Muscle Nerve 20 (1997) 665-673
191. Richards A.J. Hydroxychloroquine myopathy. J Rheumatol 25 (1998) 1642-1643
192. Ricker K., Haass A., and Glotzner F. Fenoterol precipitating myotonia in a minimally affected case of recessive myotonia congenita. J Neurol 219 (1978) 279-282
193. Riggs J.E., Schochet Jr. S.S., Gutmann L., et al. Chronic human colchicine neuropathy and myopathy. Arch Neurol 43 (1986) 521-523
194. Roberson J.R., and Dimon III J.H. Myofibrosis and joint contractures caused by injections of pentazocine. A case report. J Bone Joint Surg Am 65 (1983) 1007-1009
195. Rosenson R.S. Current overview of statin-induced myopathy. Am J Med 116 (2004) 408-416
196. Rothstein J.M., Delitto A., Sinacore D.R., et al. Muscle function in rheumatic disease patients treated with corticosteroids. Muscle Nerve 6 (1983) 128-135
197. Rousseau J.J., Reznik M., LeJeune G.N., et al. Sciatic nerve entrapment by pentazocine-induced muscle fibrosis: a case report. Arch Neurol 36 (1979) 723-724
198. Rubenstein A.E., and Wainapel S.F. Acute hypokalemic myopathy in alcoholism. A clinical entity. Arch Neurol 34 (1977) 553-555
199. Rumpf K.W., Barth M., Blech M., et al. Bezafibrate-induced myolysis and myoglobinuria in patients with impaired renal function. Klin Wochenschr 62 (1984) 346-348
200. Rutkove S.B., De Girolami U., Preston D.C., et al. Myotonia in colchicine myoneuropathy. Muscle Nerve 19 (1996) 870-875
201. Saito K., Kakei M., Uchimura S., et al. Toxic effects of chlorpromazine on red and white muscles in rats: an ultrastructural study. Toxicol Appl Pharmacol 65 (1982) 347-353
202. Saito T., Tsuboi Y., Fujisawa G., et al. An autopsy case of licorice-induced hypokalemic rhabdomyolysis associated with acute renal failure: special reference to profound calcium deposition in skeletal and cardiac muscle. Nippon Jinzo Gakkai Shi 36 (1994) 1308-1314
203. Sakai Y., Kobayashi K., and Iwata N. Effects of an anabolic steroid and vitamin B complex upon myopathy induced by corticosteroids. Eur J Pharmacol 52 (1978) 353-359
204. Santidrian S., Moreyra M., Munro H.N., et al. Effect of corticosterone and its route of administration on muscle protein breakdown, measured in vivo by urinary excretion of N tau-methylhistidine in rats: response to different levels of dietary protein and energy. Metabolism 30 (1981) 798-804
205. Scatizzi A., Di Maggio A., Rizzi D., et al. Acute renal failure due to tubular necrosis caused by wildfowl-mediated hemlock poisoning. Ren Fail 15 (1993) 93-96
206. Schmalbruch H. The early changes in experimental myopathy induced by chloroquine and chlorphentermine. J Neuropathol Exp Neurol 39 (1980) 65-81
207. Schubert D.S., Brocco K., Miller F., et al. Brief and mild alcohol intake can increase serum creatine phosphokinase. Ann Neurol 9 (1981) 200-201
208. Shoji S., and Pennington R.J. Binding of dexamethasone and cortisol to cytosol receptors in rat extensor digitorum longus and soleus muscles. Exp Neurol 57 (1977) 342-348
209. Shoji S., Takagi A., Sugita H., et al. Muscle glycogen metabolism in steroid-induced myopathy of rabbits. Exp Neurol 45 (1974) 1-7
210. Shoji S., Takagi A., Sugita H., et al. Dysfunction of sarcoplasmic reticulum in rabbit and human steroid myopathy. Exp Neurol 51 (1976) 304-309
211. Sholl J.S., Hughey M.J., and Hirschmann R.A. Myotonic muscular dystrophy associated with ritodrine tocolysis. Am J Obstet Gynecol 151 (1985) 83-86
212. Showalter C.J., and Engel A.G. Acute quadriplegic myopathy: analysis of myosin isoforms and evidence for calpain-mediated proteolysis. Muscle Nerve 20 (1997) 316-322
213. Silver R.M., Heyes M.P., Maize J.C., et al. Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. N Engl J Med 322 (1990) 874-881
214. Sinclair D., and Phillips C. Transient myopathy apparently due to tetracycline. N Engl J Med 307 (1982) 821-822
215. Sitprija V., and Boonpucknavig V. Renal failure and myonecrosis following wasp-stings. Lancet 1 (1972) 749-750
216. Slavin G., Martin F., Ward P., Levi J., et al. Chronic alcohol excess is associated with selective but reversible injury to type 2B muscle fibres. J Clin Pathol 36 (1983) 772-777
217. Song S.K., and Rubin E. Ethanol produces muscle damage in human volunteers. Science 175 (1972) 327-328
218. Sonoda Y., Gotow T., Kuriyama M., et al. Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors. Muscle Nerve 17 (1994) 891-897
219. Spargo E. The acute effects of alcohol on plasma creatine kinase (CK) activity in the rat. J Neurol Sci 63 (1984) 307-316
220. Staffa J.A., Chang J., and Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346 (2002) 539-540
221. Stauber W.T., Hedge A.M., Trout J.J., et al. Inhibition of lysosomal function in red and white skeletal muscles by chloroquine. Exp Neurol 71 (1981) 295-306
222. Steer J.H., and Mastaglia F.L. Protein degradation in bupivacaine-treated muscles. The role of extracellular calcium. J Neurol Sci 75 (1986) 343-351
223. Steer J.H., Mastaglia F.L., Papadimitriou J.M., et al. Bupivacaine-induced muscle injury. The role of extracellular calcium. J Neurol Sci 73 (1986) 205-217
224. Stein M., Bell M.J., and Ang L.C. Hydroxychloroquine neuromyotoxicity. J Rheumatol 27 (2000) 2927-2931
225. Steinness E., Rasmussen F., Svendsen O., et al. A comparative study of serum creatine phosphokinase (CPK) activity in rabbits, pigs and humans after intramuscular injection of local damaging drugs. Acta Pharmacol Toxicol 42 (1977) 357-364
226. Streicher H.Z., Gabow P.A., Moss A.H., et al. Syndromes of toluene sniffing in adults. Ann Intern Med 94 (1981) 758-762
227. Strunk S.W., Smith C.W., and Blumberg J.M. Ultrastructural studies on the lesion produced in skeletal muscle fibers by crude type A Clostridium perfringens toxin and its purified alpha fraction. Am J Pathol 50 (1967) 89-107
228. Sunderland S.K. Australian Animal Toxins (1983), Oxford University Press, Melbourne
229. Sunnasy D., Cairns S.R., Martin F., et al. Chronic alcoholic skeletal muscle myopathy: a clinical, histological and biochemical assessment of muscle lipid. J Clin Pathol 36 (1983) 778-784
230. Takahashi K., Ogita T., Okudaira H., et al. D-penicillamine-induced polymyositis in patients with rheumatoid arthritis. Arthritis Rheum 29 (1986) 560-564
231. Tam C.W., Olin III B.R., and Ruiz A.E. Loxapine-associated rhabdomyolysis and acute renal failure. Arch Intern Med 140 (1980) 975-976
232. Tao S.H., and Bolger P.M. Hazard assessment of germanium supplements. Regul Toxicol Pharmacol 25 (1997) 211-219
233. Teicher A., Rosenthal T., Kissin E., et al. Labetalol-induced toxic myopathy. Br Med J (Clin Res Ed) 282 (1981) 1824-1825
234. Thompson P.D., Nugent A.M., and Herbert P.N. Increases in creatine kinase after exercise in patients treated with HMG Co-A reductase inhibitors. JAMA 264 (1990) 2992
235. Thompson P.D., Clarkson P., and Karas R.H. Statin-associated myopathy. JAMA 289 (2003) 1681-1690
236. Tomlinson I.W., and Rosenthal F.D. Proximal myopathy after perhexiline maleate treatment. Br Med J 1 (1977) 1319-1320
237. Trout J.J., Stauber W.T., and Schottelius B.A. Chloroquine-induced alterations in phasic muscles. II. Sarcoplasmic reticulum. Exp Mol Pathol 34 (1981) 237-243
238. Ucar M., Mjorndal T., and Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 22 (2000) 441-457
239. Udezue E.O., and Harrold B.P. Hyperkalaemic paralysis due to spironolactone. Postgrad Med J 56 (1980) 254-255
240. Urbano-Marquez A., and Fernandez-Sola J. Effects of alcohol on skeletal and cardiac muscle. Muscle Nerve 30 (2004) 689-707
241. Valeriano J., Tucker P., and Kattah J. An unusual cause of hypokalemic muscle weakness. Neurology 33 (1983) 1242-1243
242. van Garsse L.G., and Boeykens P.P. Two patients with eosinophilia myalgia syndrome associated with tryptophan. Br Med J 301 (1990) 21
243. Varga J., Peltonen J., Uitto J., et al. Development of diffuse fasciitis with eosinophilia during L-tryptophan treatment: demonstration of elevated type I collagen gene expression in affected tissues. A clinicopathologic study of four patients. Ann Intern Med 112 (1990) 344-351
244. Vita G., Bartolone S., Santoro M., et al. Hypokalemic myopathy induced by fluroprednizolone-containing nasal spray. Acta Neurol (Napoli) 8 (1986) 108-109
245. Wakata N., Kawamura Y., Araki Y., et al. Study on steroid-induced muscular change. Rinsho Shinkeigaku 23 (1983) 430-435
246. Walravens P.A., Greene C., and Frerman F.E. Lovastatin, isoprenes, and myopathy. Lancet 2 (1989) 1097-1098
247. Walsh J.C., and Conomy A.B. The effect of ethyl alcohol on striated muscle: some clinical and pathological observations. Aust N Z J Med 7 (1977) 485-490
248. Watts G.F., Castelluccio C., Rice-Evans C., et al. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 46 (1993) 1055-1057
249. Wecker L., Laskowski B., and Dettbarn W.D. Neuromuscular dysfunction induced by acetylcholinesterase inhibition. Fed Proc 37 (1978) 2818-2822
250. Williams A.J., Baghat M.S., Stableforth D.E., et al. Dysphonia caused by inhaled steroids: recognition of a characteristic laryngeal abnormality. Thorax 38 (1983) 813-821
251. Wu C.M., Matsuoka T., Takemitsu M., et al. An experimental model of mitochondrial myopathy: germanium-induced myopathy and coenzyme Q10 administration. Muscle Nerve 15 (1992) 1258-1264
252. Yagiela J.A., Benoit P.W., Buoncristiani R.D., et al. Comparison of myotoxic effects of lidocaine with epinephrine in rats and humans. Anesth Analg 60 (1981) 471-480